Compare KBDC & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | SPTX |
|---|---|---|
| Founded | 2021 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 822.8M | 929.8M |
| IPO Year | 2018 | 2026 |
| Metric | KBDC | SPTX |
|---|---|---|
| Price | $12.35 | $16.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $14.50 | ★ $38.29 |
| AVG Volume (30 Days) | ★ 383.0K | 272.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $16.03 |
| 52 Week High | $15.87 | $28.38 |
| Indicator | KBDC | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 35.45 |
| Support Level | N/A | N/A |
| Resistance Level | $14.20 | $22.75 |
| Average True Range (ATR) | 0.22 | 1.49 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 3.08 | 14.27 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.